Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study

Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study

Rationale: Experimental data support the role for C5a–C5aR1 axis activation in bullous pemphigoid. We assessed the efficacy and safety of avdoralimab, a specific anti-C5aR1 mAb, for treating bullous pemphigoid. Methods: We conducted a phase 2 open-labeled randomized multicenter study. Patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Thierry Passeron, Eric Fontas, Thierry Boye, Marie-Aleth Richard, Emmanuel Delaporte, Olivier Dereure
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:JID Innovations
Subjects:
Avdoralimab
Bullous pemphigoid
C5aR1
Online Access:http://www.sciencedirect.com/science/article/pii/S2667026724000547
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2667026724000547

Similar Items